Drug intelligence / Profile preview

HIP-2101

Development stage: Unknown
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HIP-2101 is a dual delayed-release formulation of 10-mg esomeprazole developed by Hanmi Pharmaceutical. It is designed for the treatment of gastritis, specifically for patients with gastric erosions. Clinical trials have demonstrated that HIP-2101 has comparable efficacy and safety to famotidine (RLD2101) in treating gastric erosions and providing symptomatic improvement.

Brand names: Esomezol DR
Other names: esomeprazole

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on HIP-2101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HIP-2101.

Explore the full profile